Cost of tumor necrosis factor blockers per patient with rheumatoid arthritis in a multistate Medicaid population

References

• Centers for Disease Control and PreventionRheumatoid arthritis2010 Available from: http://www.cdc.gov/arthritis/basics/rheumatoid.htmAccessed May 5, 2014
   Google Scholar
• HelmickCGFelsonDTLawrenceRCfor the National Arthritis Data WorkgroupEstimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part 1Arthritis Rheum200858152518163481
   PubMed Web of Science ®Google Scholar
• MurdacaGSpanoFPuppoFLong-term treatment of rheumatoid arthritis with adalimumabOpen Access Rheumatology201354349
   PubMedGoogle Scholar
• BonafedeMMGandraSRWatsonCCost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysisAdv Ther20122923424822411424
   PubMed Web of Science ®Google Scholar
• SchabertVFWatsonCGandraSRAnnual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United StatesJ Med Econ20121526427522115327
   PubMedGoogle Scholar
• BonafedeMJosephGJPrincicNHarrisonDJAnnual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitisJ Med Econ201391120112823808901
   PubMedGoogle Scholar
• Immunex Corporation. Enbrel® (etanercept)Prescribing informationThousand Oaks, CA, USAImmunex Corporation2012
   Google Scholar
• Abbott Laboratories. Humira® (adalimumab)Prescribing informationNorth Chicago, IL, USAAbbott Laboratories2012
   Google Scholar
• Centocor Ortho Biotech, Inc. Remicade® (infliximab)Prescribing informationMalvern, PA, USACentocor Ortho Biotech Inc2011
   Google Scholar
• FisherMPolinskiJServiAPrior authorization for biologic disease-modifying antirheumatic drugs: a description of US Medicaid programsArthritis Rheum2008591611161718975371
   PubMed Web of Science ®Google Scholar
• BullanoMFMcNeeleyBJYuYFComparison of costs associated with the use of etanercept, infliximab, and adalimumab for the treatment of rheumatoid arthritisManag Care Interface200619475317017313
   PubMedGoogle Scholar
• EtemadLYuEBWankeLADose adjustment over time of etanercept and infliximab in patients with rheumatoid arthritisManag Care Interface200518212715889759
   PubMedGoogle Scholar
• GilbertTDJrSmithDOllendorfDAPatterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort studyBMC Musculoskelet Disord200453615485582
   PubMed Web of Science ®Google Scholar
• MootsRJHaraouiBMatucci-CerinicMDifferences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practiceClin Exp Rheumatol201129263421345289
   PubMed Web of Science ®Google Scholar
• OllendorfDAKlingmanDHazardEDifferences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care populationClin Ther20093182583519446156
   PubMed Web of Science ®Google Scholar
• BlomMKievitWFransenJThe reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritisJ Rheumatol2009362171217719723902
   PubMed Web of Science ®Google Scholar
• Medicaid.govCost sharing out of pocket costs Available from: http://www.medicaid.gov/Medicaid-CHIP-Program-Information/By-Topics/Cost-Sharing/Cost-Sharing-Out-of-Pocket-Costs.htmlAccessed May 5, 2014
   Google Scholar
• Medicare 2011 National Physician Fee Schedule Relative Value File, April 2012 Update Available from: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSchedAccessed June 3, 2014
   Google Scholar
• SchabertVFBruceBFerrufinoCFDisability outcomes and dose escalation with etanercept, adalimumab, and infliximab in rheumatoid arthritis patients: a US-based retrospective comparative effectiveness studyCurr Med Res Opin20122856958022236091
   PubMed Web of Science ®Google Scholar
• BonafedeMMGandraSRFoxKMTumor necrosis factor blocker dose escalation among biologic naive rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiationJ Med Econ20121563564322332705
   PubMedGoogle Scholar
• BarteldsGMKrieckaertCLNurmohamedMTDevelopment of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-upJAMA20113051460146821486979
   PubMed Web of Science ®Google Scholar
• AgarwalSKMaierALChibnikLBPattern of infliximab utilization in rheumatoid arthritis patients at an academic medical centerArthritis Rheum20055387287816342095
   PubMed Web of Science ®Google Scholar
• BergerAEdelsbergJLiTTDose intensification with infliximab in patients with rheumatoid arthritisAnn Pharmacother2005392021202516288073
   PubMed Web of Science ®Google Scholar
• WuEChenLBirnbaumHRetrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritisCurr Med Res Opin2008242229224018577308
   PubMed Web of Science ®Google Scholar
• OgaleSHitrayaEHenkHJPatterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort studyBMC Musculoskelet Disord20111220421929807
   PubMed Web of Science ®Google Scholar
• LiPBlumMVon FeldtJAdherence, discontinuation, and switching of biologic therapies in medicaid enrollees with rheumatoid arthritisValue Health20101380581221054657
   PubMed Web of Science ®Google Scholar
• HolahanJBuettgensMCarrollCDornSThe cost and coverage implications of the ACA Medicaid expansion: national and state-by-state analysisThe Urban Institute2012 Available from: http://www.kff.org/medicaid/upload/8384.pdfAccessed November 17, 2012
   Google Scholar
• Department of Health and Human Services, Centers for Medicare and Medicaid ServicesFrequently asked questions on exchanges, market reforms and Medicaid12102012 Available from: http://www.medicaid.gov/State-Resource-Center/Frequently-Asked-Questions/Downloads/Governor-FAQs-12-10-12.pdfAccessed December 18, 2012
   Google Scholar
• IikuniNSatoEHoshiMThe influence of sex on patients with rheumatoid arthritis in a large observational cohortJ Rheumatol20093650851119208610
   PubMed Web of Science ®Google Scholar
• TengstrandBAhlménMHafströmIThe influence of sex on rheumatoid arthritis: a prospective study of onset and outcome after 2 yearsJ Rheumatol20043121422214760787
   PubMed Web of Science ®Google Scholar
• American Congress of Obstetricians and GynecologistsProtect Medicaid and Women’s Health Available from: http://www.acog.org/~/media/Departments/Government%20Relations%20and%20Outreach/2012ProtectMedicaid.pdfAccessed November 17, 2012
   Google Scholar